The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Lol
This already seems to be shaping for a day of, "Let's all think of excuses for Alan".
It is a romantic notion that Avacta can stay independent long enough and retain full ownership of most of its platforms long enough to become a pharma giant, thus extracting maximum long-term shareholder value for us all.
However, the longer we stay independent the more likely it is that we don't actually have what big pharma really wants, making it more unlikely we achieve greatness on our own (notwithstanding the huge amounts of cash we would need to do it on our own in the first place).
This is business. We really need to have what big pharma wants to make good returns here. The quicker the better in my view.
Buying LD was (IMHO) a genius move on many fronts.
Big cash runway.
Positively cash generative to service the debt and decrease overall cash burn.
A message to the market that "we could do this on our own if you don't come up with some serious offers".
A profitable business to continue with and grow from should therapeutics be sold.
This is the problem Kenny for you here having so much history and so much emotional attachment with this share.
From an outsider's perspective, this has been a classic pump and dump. Once France had pumped it up on Monday there was no way it was going further on Tuesday. Sad to say it, but only the LTHs here have been sucked in by this. Hopefully, some of you managed to trade it and get some profit back, but most will have bought more and got themselves in a deeper hole.
Covid being rife does not automatically equal £millions in profit (and therefore a justified SP rise) for NCYT.
Reading the comments posted here the last few days from those thinking it does has been a real eye opener.
"all opinions and predictions are allowed in a democracy, even silly ones like yours"
Indeed.
You're no stranger to a ridiculous prediction yourself eh JR?
"some posters on here think testing is of no benefit."
Unless testing is done systematically and in the very early hours of a carrier being infectious, (and then that carrier self-isolating), testing has no benefit. Usually, by the time someone tests positive, it is already too late to have stopped them from infecting others. This is why it spread rampantly around the globe in the first place.
There is absolutely no suggestion in the RNS that any press will be invited.
As usual, we seem to be getting a little ahead of ourselves here with the science day. Attendees variously being described as "the great and the good" of the oncology world and of KOL's needing to book flights etc.
All we know is that "City Analysts and Fund Managers" will be invited and that we will "hear from selected KOL's" from the oncology field.
"to base information on a Macro timeline and say we have delays etc, when the micro timeline is out is ridiculous and only serves a trading agenda"
To say there have been no delays when there have clearly been delays. That must serve a LTH's agenda then? Or is it merely bizarre?
"there is no way a company like this would be allowed to market anything with out evidence."
eh??
So whoever "allowed" them to put up the sign has seen the evidence it works Kong??
Lol
Madness in here
"To conclude, Covid discussion adds no value whatsoever."
Who said it added value?
99.9% of the twaddle on this board adds no value whatsoever.
There is a very strange group of people on here who have their heads stuck so far up their own A-holes, that they think they need to butt into other people's conversations (even though they have no interest in the subject).
"The fact this BB is engaging in (covid) LFT discussion nearly 500 days into a first in human therapeutics trial is testament to just how persistent Touk’s trolling is."
Maybe, just maybe RAH, people on the Avacta discussion board want to talk about other areas of AVACTA's business.
Makes a nice change from reading your copy/paste posts for the 164th time, I suppose.
Ice,
Relaunching the test is the easy bit.
Selling them at a profit is the bit I don't think we can do.
What makes you think we can?
I read loads of RNS where he was very positive about the last launch.
a) We don't have a test
b) We couldn't sell them even if we did
The covid testing market is irrelevant to Avacta.
"millions of folk are still testing regularly in this country and worldwide for various reasons"
You know that how? Lol
Even if they are, why would they suddenly ditch their favourite Covid Test and use AffiDX instead?
We have a well-proven history in NOT being able to sell one of the "best covid tests in it's class in the world"
"This net figure, which is a target agreed between MOS and EFC and not a forecast or guidance"
Good place to start, yes.
These "target" revenue numbers are pie in the sky. They mean Jack.
As has been posted here today and before. Do the Maths.
How many Sales, and at what price? How many drops? How much can they charge and how big is the secondary market going to be?
And time on these contracts is already running out. No investor with more than half an actual brain cell would trust these "targets" on blind faith alone.
MOS needs to give at least some crumbs of evidence, (real factual evidence), that these revenues are achievable together with a believable plan of action.
No such evidence yet exists. No such plan yet exists.
So you didn't want to tell us more about the inside info you alleged you got the other day?
But you are delighted to tell us all you have loaded up on shares after getting that alleged inside info?
Hope you are good at covering your tracks.
"and I’d love to say why!"
Go ahead. The floor is yours. What is stopping you?
" you poor sad narcissistic nonentities", said the sad narcissistic nonentity.
That could be the first paragraph of your long-awaited autobiography Ophidian.
I hope for the sake of all your recent "chomping" that you are right.
We really are incredibly fortunate to have builders on here that know more about cancer treatments than complex cancer teams.